(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 14.36% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.33%.
Alpha Teknova's revenue in 2026 is $40,520,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,351,051,495, with the lowest TKNO revenue forecast at $2,227,210,408, and the highest TKNO revenue forecast at $2,448,688,215. On average, 8 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,659,716,428, with the lowest TKNO revenue forecast at $2,457,744,530, and the highest TKNO revenue forecast at $2,812,012,563.
In 2028, TKNO is forecast to generate $3,358,660,304 in revenue, with the lowest revenue forecast at $3,066,929,072 and the highest revenue forecast at $3,628,956,471.